Our clients in Bosnia and Herzegovina include multinational concerns as well as medium-sized companies from all business sectors who, like us, have recognised the potential of this fast-growing market. We have been assisting our clients with market entry into Bosnia and Herzegovina since 2007, and every year we have successfully completed many projects together - mainly in the fields of renewable energies, construction and infrastructure, but also for banks, health care institutions and life sciences companies.

Do you already have a presence in Bosnia and Herzegovina, or are you planning to launch your business here in the near future? A seasoned CMS legal team of 10 with national and international experience and an excellent local network are here to expertly guide you through the complexities of the local legal system.

While the legal system of Bosnia and Herzegovina is stable and functioning, the political reality of a country divided into two jurisdictions, each with its own constitution and a decentralised state power structure, lends an element of complexity to the overall situation. The reality is that there are few national government control mechanisms and therefore no unified legislation. This means, for example, that even in important areas such as company law, each of the two entities has its own unique system. Our legal team fully understand how to use this statutory framework to your commercial advantage.

Since Bosnia and Herzegovina is in need of foreign investment, the barriers to investment are steadily being taken down and efforts to align national laws with EU law are moving ahead. While these developments undoubtedly increase the country's ability to attract investment, unresolved issues regarding trade and company law remain.

If you too are looking to leverage your opportunities in Bosnia and Herzegovina and are in search of legal advice and support from an experienced law firm with an international perspective, kindly contact us any time online, by email or by telephone.

more less

Location

CMS Reich-Rohrwig Hainz d.o.o.
Ul. Fra Anđela Zvizdovića 1
71000 Sarajevo
Bosnia and Herzegovina
Open Google Maps

Feed

30/01/2023
Emer­ging Europe M&A Re­port 2022/2023
The year 2022 star­ted with vari­ous chal­lenges, in­clud­ing rising in­fla­tion and en­ergy prices. Then the Rus­si­an in­va­sion of Ukraine ad­ded yet an­oth­er one. Non­ethe­less, the M&A mar­ket in emer­ging European coun­tries proved to be ex­tremely re­si­li­ent. The re­gion saw M&A activ­ity main­tain a steady pace, though deal val­ues were not­ably lower. Also, vari­ations could be ob­served across ter­rit­or­ies and sec­tors. While 2022 brought a unique set of chal­lenges, deal­mak­ing largely com­pared fa­vour­ably to pre-pan­dem­ic levels.Wel­come to the 2022/23 edi­tion of the Emer­ging Europe re­port.
27/01/2023
Quantum com­put­ing pat­ent in­crease is far above av­er­age
On Wed­nes­day 25 Janu­ary 2023, the European Pat­ent Of­fice (EPO) is­sued their In­sight Re­port in­to quantum com­put­ing and pat­ents. In their Re­port, the EPO con­sidered quantum com­put­ing pat­ents in gen­er­al...
25/01/2023
Key out­comes from COP-15
At the end of 2022, the 15th Con­fer­ence of Parties of the United Na­tions Con­ven­tion on Bio­lo­gic­al Di­versity cul­min­ated in a new Glob­al Biod­iversity Frame­work to 2030. Twenty three tar­gets re­quire broad...
18/01/2023
What is the sig­ni­fic­ance of a clin­ic­al tri­al pro­tocol as pri­or art at the...
The EPO Ap­peal Board has fur­ther re­fined their view on when pri­or art dis­clos­ures of clin­ic­al tri­al pro­to­cols are an is­sue for pat­entab­il­ity of med­ic­al use claims. De­cision T1806/18 In de­cision T1806/18...
23/12/2022
EIOPA re­leases an­nu­al re­port on sanc­tions un­der IDD in 2021
On 20 Decem­ber, the European In­sur­ance and Oc­cu­pa­tion­al Pen­sions Au­thor­ity (EIOPA) re­leased the an­nu­al re­port on sanc­tions im­posed by na­tion­al com­pet­ent au­thor­it­ies un­der the In­sur­ance Dis­tri­bu­tion Dir­ect­ive...
19/12/2022
European Com­mis­sion’s green light to €14.3 mil­lion Croa­tian com­pens­a­tion...
The  Croa­tian  au­thor­it­ies,  which  we  as­sisted  in  the  pre­par­a­tion  of  the  file, no­ti­fied in Au­gust 2022 to the European Com­mis­sion, a meas­ure aimed at par­tially com­pens­at­ing the dam­age...
16/12/2022
Arm­chair in­ven­tions part 2:  Pre­lim­in­ary opin­ion on plaus­ib­il­ity at the...
The is­sue of plaus­ib­il­ity was pre­vi­ously re­ferred to the En­larged Board of Ap­peal (EBA), the highest ju­di­cial au­thor­ity at the European Pat­ent Of­fice (EPO). Our art­icle on the re­fer­ral can be found here...
12/12/2022
Glob­al Life Sci­ences & Health­care For­um 2022: Fa­cing the op­por­tun­it­ies...
Di­git­al ad­vances and in­nov­at­ive ther­apies are push­ing the bound­ar­ies of health and the leg­al world has to keep pace Life sci­ences are fizz­ing with in­genu­ity and in­nov­a­tion with re­volu­tion­ary gene and...
05/12/2022
EU Com­mis­sion pro­poses to mod­ern­ise product li­ab­il­ity rules for green and...
Cur­rent product li­ab­il­ity rules, based on the 85/374/EGK Product Li­ab­il­ity Dir­ect­ive (PLD), are nearly 40 years old and no longer suit­able for the mod­ern di­git­al age. Among oth­er things, the PLD is un­cer­tain...
22/11/2022
Glob­al Life Sci­ences & Health­care For­um 2022: Life Sci­ences are reap­ing...
Di­git­al trans­form­a­tion in life sci­ences is cre­at­ing op­por­tun­it­ies to counter health­care’s most in­tract­able prob­lems from treat­ing rare dis­eases to ac­cel­er­at­ing dia­gnostics and re­du­cing treat­ment back­logs...
21/11/2022
State aid: The Court of Justice of the EU an­nuls the Com­mis­sion’s de­cision...
On 8 Novem­ber 2022, the Court of Justice of the EU (CJEU) an­nulled the judg­ment of the Gen­er­al Court held on 24 Septem­ber 2019, which re­jec­ted the ac­tion brought by the Grand Duchy of Lux­em­bourg and Fi­at...
10/11/2022
US ad­opts Ex­ec­ut­ive Or­der to im­ple­ment EU-US Data Pri­vacy Frame­work
After an­noun­cing a polit­ic­al agree­ment on 25 March 2022, the US gov­ern­ment has now an­nounced more de­tails on how it in­tends to put mass sur­veil­lance by in­tel­li­gence agen­cies on a rule-of-law foot­ing...